- Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinated
- The AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herd
- No additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the fall months and uptick in virus counts
- The reallocation of funds for further vaccine development has reduced the amount spent on testing efforts causing concern for epidemiologists due to the lack of variant tracking
The COVID-19 pandemic, from the start, has been characterized by the high unpredictability of the virus. Despite the best efforts of the scientific community to use the historical data and patterns of previous viruses, it is becoming apparent that the original presumptions are no longer valid. The original hypothesis was that once enough people created an immunity to COVID-19, it would stop the virus dead in its tracks; unfortunately, what they are learning is that herd immunity is unlikely to happen.
Herd immunity occurs when a virus can’t spread because it keeps encountering people who have become immune to the specific virus. The idea is that a small group of people lacking resistance to the virus can be protected by the immune herd because it is less likely to spread to them. Even though the mentality that herd immunity can be successful through immunizations, scientists no longer believe that this is an appropriate management strategy for COVID-19 long-term.
Two years after a COVID-19 vaccine was made available, fewer than 70% of Americans are fully vaccinated (https://ibn.fm/lcOKY). The pockets of unvaccinated people who lack any type of immunity to this ever-changing virus only provide the potential for the virus to grow and mutate as it spreads. Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, has partnered with Premier Medical Laboratory Services to provide individuals with personalized information regarding their immune system via the AditxtScore(TM). The score can be used to provide those tested with important answers to questions like:
- Are antibodies present?
- How are these antibodies present – vaccine or natural immune system response?
- Will this immunity status provide protection from the virus in the future?
- What is the best approach to creating immunity for that individual?
“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” Kevin Murdock, CEO of Premier Medical Laboratory Services, stated (https://ibn.fm/pbmD3). “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.”
With the potential for herd immunity off the table, and federal COVID funds dwindling, supply rationing has begun. Of the current budget, the Biden Administration has reallocated $5 billion to purchase updated versions of the vaccine for fall. Since Congress has approved no new funding, the Administration is forced to use the remaining budget to consider the longer-term solutions, like fall when virus uptick increases. At this time, epidemiologists are concerned about the blind spots created due to the shift in focus from testing to more vaccine development. Without the increased testing efforts, it becomes impossible to track and isolate variants. Without the funding, further development on the COVID-19 front will be less likely to be sustainable.
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.